PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of neurologyNeurologyAmerican Academy of Neurology
 
Neurology. Nov 13, 2012; 79(20): 2061–2066.
PMCID: PMC3511918
Traumatic brain injury, paraquat exposure, and their relationship to Parkinson disease
Pei-Chen Lee, PhD,corresponding author
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers' Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • This work was supported by the National Institute of Environmental Health Science [grant numbers R01ES010544 and U54ES012078] and the National Institute of Neurological Disorders and Stroke [grant number P50NS038367]; in addition, initial pilot funding was provided from NIH P30ES007048 and a pilot grant by the American Parkinson Disease Association.
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Yvette Bordelon, MD, PhD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • Sonexa. Consultancy
Speakers' Bureaus:
  • Teva, Lundbeck
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NINDS. K 23 award 2008-2013
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • Michael J Fox foundation grant 2009-2011
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
Jeff Bronstein, MD, PhD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • Neurology International, Associate editor, 2011-present
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers' Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • 1) NIEHS, 2R01-ES010544, Co-I, 02/01/11-01/31/15, 2) NIEHS, PI, 5R21ES16446-2, 3/6/09-2/28/11, 3) NINDS, Co, 5P50NS038367-07, 5/1/06-4/30/12, 4) NIEHS, Project PI, 1P01ES016732-08/10/2008-6/2013, 5) Veterans Administration Healthcare System Center, PI, no number, 5/2001-ongoing
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
and Beate Ritz, MD, PhD
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers' Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NIEHS # ES013717 2007-current PI, NINDS #NS038367 2006-current Co-I, NIEHS #U54ES12078, 2008-current Co-I, #R03 ES017119-0 and R21ES016379-01A1 2008-current Co-I, Department of Defense (DOD)# X81XWH-07-1-0005 2006-current PI, US EPA #R833629 and #010003LA Co-I, California Air Resources Board #07309, HRSA 1R40MC08726
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • Foundation for Psychocultural research (TheFPR.org) funds students and postdocs at UCLA
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
From the Department of Epidemiology, Fielding School of Public Health (P.-C.L., B.R.), and Department of Neurology, School of Medicine (Y.B., J.B., B.R.), University of California at Los Angeles, Los Angeles.
corresponding authorCorresponding author.
Correspondence & reprint requests to Dr. Lee: pel27/at/ucla.edu
Study funding: This work was supported by the National Institute of Environmental Health Science (grant numbers R01ES010544 and U54ES012078) and the National Institute of Neurological Disorders and Stroke (grant number P50NS038367); in addition, initial pilot funding was provided from NIH P30ES007048 and a pilot grant by the American Parkinson Disease Association.
Go to Neurology.org for full disclosures. Disclosures deemed relevant by the authors, if any, are provided at the end of this article.
Received April 22, 2012; Accepted July 26, 2012.
Objectives:
Traumatic brain injury (TBI) increased risk of Parkinson disease (PD) in many but not all epidemiologic studies, giving rise to speculations about modifying factors. A recent animal study suggested that the combination of TBI with subthreshold paraquat exposure increases dopaminergic neurodegeneration. The objective of our study was to investigate PD risk due to both TBI and paraquat exposure in humans.
Methods:
From 2001 to 2011, we enrolled 357 incident idiopathic PD cases and 754 population controls in central California. Study participants were asked to report all head injuries with loss of consciousness for >5 minutes. Paraquat exposure was assessed via a validated geographic information system (GIS) based on records of pesticide applications to agricultural crops in California since 1974. This GIS tool assesses ambient pesticide exposure within 500 m of residences and workplaces.
Results:
In logistic regression analyses, we observed a 2-fold increase in risk of PD for subjects who reported a TBI (adjusted odds ratio [AOR] 2.00, 95% confidence interval [CI] 1.28–3.14) and a weaker association for paraquat exposures (AOR 1.36, 95% CI 1.02–1.81). However, the risk of developing PD was 3-fold higher (AOR 3.01, 95% CI 1.51–6.01) in study participants with a TBI and exposure to paraquat than those exposed to neither risk factor.
Conclusions:
While TBI and paraquat exposure each increase the risk of PD moderately, exposure to both factors almost tripled PD risk. These environmental factors seem to act together to increase PD risk in a more than additive manner.
Parkinson disease (PD), the second most common neurodegenerative disorder affecting 1%–2% of the population over 65 years of age, is characterized by progressive loss of dopamine neurons in substantia nigra pars compacta, leading to bradykinesia, rigidity, postural instability, and resting tremor as the cardinal motor features. It is widely acknowledged that PD etiology is most likely multifactorial. Lifestyle habits such as smoking and caffeine intake, genetic polymorphisms, environmental exposures to pesticides or metals, long-term exposure to certain medications, and interactions between these factors collectively appear to contribute to disease development. We have previously reported 2- to 3-fold increases in risk of developing PD when exposed to specific types or classes of pesticides, especially for combined exposures to paraquat and maneb, and for patients who carry genetic polymorphisms in susceptibility genes.1,2
In the past 20 years, many but not all studies of traumatic brain injury (TBI) have linked head injuries with or without loss of consciousness to PD.310 We speculated that TBI may require additional risk or susceptibility factors in order to cause PD, which has sometimes been referred to as the “multiple hit” hypothesis of PD.11 Recently, an animal study demonstrated that even though a single exposure to a mild TBI was sufficient to cause a progressive loss of nigrostriatal dopaminergic neurons, the number of dopaminergic neurons lost was much larger when TBI was accompanied by exposure to paraquat at a dose that by itself did not cause a significant loss of nigrostriatal dopaminergic neurons.12 Specifically, an insult such as TBI may simply increase the vulnerability of dopaminergic neurons to additional insults, including toxic agents such as pesticides. Herein, utilizing our unique exposure data from a population-based case-control study with a well-characterized PD phenotype, we present evidence that exposure to both TBI and paraquat in humans increases risk for developing PD.
Subjects
This case-control study enrolled patients with incident idiopathic PD between January 1, 2001, and January 1, 2007, and population-based controls from 3 mostly rural agricultural counties (Kern, Tulare, Fresno) in central California between 2002 and 2011. Subject recruitment methods13 and case definition criteria14 have been described in detail elsewhere.
Cases with a PD diagnosis within 3 years of enrollment (2001–2007), not in the last stages of a terminal illness, residing in the tri-county study area at the time of recruitment, and residing in California for at least 5 years before recruitment were recruited through neurologists, large medical groups, and public service announcements. Of 1,167 patients with PD initially identified, 604 did not meet eligibility criteria: 397 had their initial PD diagnosis more than 3 years prior to recruitment, 134 lived outside the tri-county area at the time of recruitment, 51 had a diagnosis other than PD, and 22 were too ill to participate. Of the 563 eligible cases, 90 could not be examined (56 declined to participate or moved away, 18 had become too ill to be examined, and 16 died prior to the scheduled appointment). Of the 473 subjects examined by University of California at Los Angeles movement disorder specialists (J.B. and Y.B.), 94 did not meet published criteria for idiopathic PD15,16 when examined or re-examined during the initial study period, an additional 13 were reclassified as not idiopathic PD during our follow-up study,17 6 subjects withdrew between examination and interview, and 3 cases were diagnosed after January 2007, our enrollment close-out date. Only the remaining 357 PD cases contributed to this analysis.
Eligibility criteria for controls included not having Parkinson disease, being at least 35 years of age, residing in the tri-county study area at the time of recruitment, and residing in California for at least 5 years prior to recruitment. Population-based controls were recruited initially from Medicare lists (2001) and, after the Health Insurance Portability and Accountability Act (HIPAA), from residential tax assessor records from the tri-county area. Two sampling strategies were implemented to increase enrollment success and achieve representativeness of the control population, including 1) random selection of residential parcels which we enrolled via mail and phone13; and 2) random selection of 5 households per cluster, each visited in person by study staff members up to 4 times to determine eligibility and to recruit subjects. We defined clusters based on the random selection of 1 residential address in the tri-county area plus 4 other addresses in close proximity to the selected address.
Of the 1,212 potential controls contacted through the first sampling strategy, 457 were ineligible: 409 were <35 years of age, 44 were too ill to participate, and 4 primarily resided outside the study area. From among 755 eligible population controls, 409 declined, became too ill to participate, or moved out of the area after screening and prior to enrollment. Another 5 controls provided only partial information and were excluded. Of the 4,756 individuals screened for eligibility through the second sampling strategy, 3,515 were ineligible (88% due to age criteria). From 1,241 eligible population controls, 634 declined participation. There were 607 population controls enrolled under the second sampling strategy. We also excluded 183 controls who completed only an abbreviated questionnaire, 8 controls who lacked relevant exposure information, and 3 cognitively impaired controls. Thus, our study included 341 controls identified by mail or phone and 413 controls identified in-person (total n = 754) with all information necessary for inclusion in this analysis.
Standard protocol approvals, registrations, and patient consents
Written informed consent was obtained from all subjects, and the study was approved by the UCLA Institutional Review Board.
Traumatic brain injury and ambient paraquat exposure
Cases and controls provided information on demographics, detailed lifetime residential, workplace address, and medical histories, and behavioral risk factors in interviews. As part of the medical history interview, participants reported ever having experienced a head injury with loss of consciousness for over 5 minutes, their age at the time of the event, and whether they had been hospitalized. We defined TBI as having reported a head injury with loss of consciousness for more than 5 minutes.
Ambient residential and workplace exposures to paraquat were estimated for each study participant using a validated geographic information system (GIS)–based system.18 This GIS system combined pesticide use report data collected by the California Department of Pesticide Regulation since 1974, land use maps created by the California Department of Water Resources, and geocoded address information for all reported residential and workplace addresses. The GIS-based system estimates ambient pesticide exposure around homes or workplaces resulting from pesticide applications to agricultural crops, and has been described in detail elsewhere.19,20 Briefly, for each participant's residential and workplace address from 1974 to 1999, we estimated pounds of paraquat applied per acre for a 500-m buffer around the home or workplace, weighting the total poundage by the proportion of the acreage treated. We then calculated an average study period exposure estimate by summing the year-specific values and dividing by the total study period (26 years, from 1974 to 1999). We considered participants exposed to paraquat if they had an average study period exposure greater than 0 at both their residential and their workplace addresses. We calculated paraquat exposure up to 1999 in order to restrict our exposure of interest to the time before most of our patients with PD were diagnosed; i.e., our patients were first diagnosed between 1999 and 2007.
Statistical analysis
Demographic characteristics were compared between cases and controls using the Student t test for continuous variables and the Pearson χ2 test for categorical variables. To assess the main effects of both TBI and paraquat on PD, we employed unconditional logistic regression analyses to calculate odds ratios (ORs) and 95% confidence intervals (CIs). We examined multiplicative interactions between TBI and paraquat by introducing a product term into logistic regression models. It has been suggested that biological and public health interactions should be assessed on an additive rather than a multiplicative scale; a positive departure from additivity of the estimated effects means that the combined effect of 2 exposures is larger than the sum of each individual effect.21 Thus, we also examined interactions on the additive scale by calculating the relative excess risk due to interaction (RERI), which is defined as RR11 − RR10 − RR01 + 1, where RRij denotes the relative risk and i and j are used to denote the presence (=1) or absence (=0) of 2 separate exposures. We used the delta method proposed by Hosmer and Lemeshow22 to calculate the 95% CI for RERI. Since the incidence of PD is rare, we used ORs to estimate relative risks (RR). In all regression models, we adjusted for age (continuous, defined as age at PD diagnosis for cases and age at enrollment for controls), gender (male, female), smoking status (ever, never), race (Caucasian, non-Caucasian), county (Fresno, Tulare, Kern), and education (continuous, in years). For main effects, we conducted sensitivity analyses stratifying by gender. For interaction analyses, we performed additional sensitivity analyses excluding 1) participants who reported head trauma that had occurred within 10 years of index date (PD diagnosis for cases or interview date for controls); 2) those not hospitalized at the time of the head injury; and 3) population controls recruited from the same cluster who had lived at the recruitment address for more than 2 years prior to 1999 (i.e., we excluded 23 controls from 21 residential clusters by randomly sampling and including only 1 control from each such cluster). Subjects with missing head trauma information (n = 23) were excluded from main and interaction analyses.
Participants with idiopathic PD were more likely to be male than population controls (table 1). Patients with PD were also slightly older and less likely to report ever having smoked cigarettes. The reported frequency of head trauma with over 5 minutes of unconsciousness was higher among cases than controls (table 2). We estimated a 2-fold increase in risk for developing PD for those experiencing TBI, and the effect estimate was slightly stronger for women than men (women, adjusted OR [AOR] = 2.61, 95% CI = 1.32–5.16; men, AOR = 1.71, 95% CI = 0.94–3.11). Up to 41% of our study population (n = 460) had ever been exposed to paraquat both at home and at workplaces (table 2). There was a moderate association with PD for those exposed residentially and occupationally, but no difference between men and women (results not shown).
Table 1
Table 1
Demographic characteristics of the study population by PD status
Table 2
Table 2
Associations between traumatic brain injury, ambient paraquat exposure, and Parkinson disease
When examining combined effects of ambient paraquat exposures and TBI, we observed a 3-fold risk increase for subjects who reported a TBI and had also been exposed to paraquat at both home and workplaces, compared with persons who had never experienced TBI or been exposed to paraquat (table 3). Compared to those without either TBI or paraquat exposure, we observed 31%–78% increases in risk for those exposed to paraquat but who had not experienced TBI, and those who had experienced TBI but had not been exposed to paraquat. When examining interactions on an additive scale, we observed a higher than additive risk for those with combined exposure to paraquat and TBI (RERI = 0.92, 95% CI = −1.33 to 3.16; figure). All estimated effect sizes were very similar when we restricted our population to head traumas that had occurred 10 years prior to the index date (data not shown). Similarly, effect estimates for interactions did not change notably when we excluded participants who had not been hospitalized for head injuries or controls from clusters in which more than 1 resident had been living in their home for more than 2 years prior to 1999 (data not shown).
Table 3
Table 3
Effect estimates (ORs and 95% CI) for interactions between ambient residential and workplace exposures to paraquat, traumatic brain injury, and Parkinson disease
Figure
Figure
Relative risks (estimated from odds ratios) contributions from traumatic brain injury (TBI), paraquat, and combined TBI and paraquat exposures
Our study suggests a combined effect of 2 environmental exposures, TBI and paraquat exposure, on PD development that is larger than each component effect. These results in humans are supported by findings from a recent animal study in which the combination of experimental head trauma and subthreshold paraquat doses led to increased nigrostriatal dopaminergic neuron loss, and greater induction of α-synuclein accumulation and inflammation compared with experimental head trauma treatment alone.12
Our results for TBI and PD are consistent with findings from previous studies that reported head injuries as being associated with PD.3,6,7,9,10 A twin study reported a 4-fold increased risk for developing PD among subjects self-reporting a prior head injury (OR = 3.8, 95% CI = 1.3–11). Two case-control studies assessed head injuries based on medical record review rather than participant recall.3,8 One of these was a small study (196 patients with PD) that found associations for subjects with severe head injury requiring hospitalization, but included only 9 head trauma hospitalizations.3 The other very large medical record linkage study conducted in Denmark reported a 50% increase in risk of developing PD after hospital treatment for head injuries within 10 years prior to a PD diagnosis.8 This is consistent with our estimate for subject reports of head injuries requiring hospitalization (AOR = 1.77, 95% CI = 0.99–3.17).
Our new results for ambient paraquat exposure confirm our previous findings, but with a larger control group, and including exposures both at residences and workplaces.23 A previous study in Taiwan reported occupational paraquat exposure to increase PD risk (OR = 3.2, 95% CI = 2.41–4.31).24 More recently, a cohort study in the United States also reported ever being exposed to paraquat as being associated with PD (OR = 2.5, 95% CI = 1.4–4.7).25 Although the effect estimates for PD and paraquat from these 2 studies are greater than ours (AOR = 1.36, 95% CI = 1.02–1.81), these results cannot easily be compared to our findings, due to differences in the types of exposure, i.e., occupational vs ambient paraquat exposures.
Similar to most previous studies, we collected TBI information through interviews, which might introduce bias due to differential recall by cases compared with controls. However, a previous head trauma and PD study6 observed perfect agreement between self-reports and medical record retrieval of information regarding head injuries in a subset of their sample. These authors also suggested that differential recall for head injuries is most likely for events that occur closer in time to PD onset. When we excluded TBI reports close to PD onset, we observed similar size associations, suggesting no differences in recall depending on PD diagnosis. A major strength of our study is the availability of our GIS-based modeling system for long-term ambient residential and workplace paraquat exposures, using California pesticide use records. This exposure assessment tool avoids differential recall bias for historical exposure; however, nondifferential misclassification of exposure cannot be ruled out (e.g., due to geocoding errors and uncertainties concerning pesticide drift).
There are a number of biological mechanisms that may explain the associations we observed. TBI is known to induce an inflammatory cascade and accumulation of α-synuclein and tau, 2 proteins that are major components of Lewy bodies.2631 Furthermore, TBI may contribute to PD through disruption of the blood–brain barrier and mitochondrial function.3235 Most recently, a pooled epidemiologic study36 observed an association (OR = 3.5, 95% CI = 1.4–9.2) between head injury and PD, but only among carriers of the α-synuclein (SNCA) Rep1 promoter risk allele, which has been previously associated with an increased risk of PD.3638 In experimental animal studies, paraquat exposure can induce reactive oxygen species production in the brain, which may lead to loss of nigral dopaminergic neurons.39,40 This, combined with recent experimental animal data,12 suggests that the physiologic process triggered by a head injury may increase the vulnerability of neurons to insults from neurotoxic pesticides, with the combination increasing the risk of PD more than each exposure on its own.
A recent animal study that examined the combined effects of TBI (first exposure) and low-dose paraquat exposure (subsequent exposure) in rats observed a synergistic effect of both exposures on nigrostriatal dopaminergic neuron loss with exposure to paraquat 3 and 6 days after TBI; however, this synergistic effect was not observed when paraquat was administered 21 and 22 weeks after TBI.12 In the present study, we were unable to address temporality of TBI and paraquat exposures, since pesticide records were only available after 1974. Many of our study participants reported TBIs that had occurred at a young age (mean = 27 years; range = 2–82), i.e., during a period when pesticide exposures were not yet recorded in the California system. Another limitation of our study is that we were unable to examine the effect measure modification by gender since the relatively small number of cases exposed to both agents did not provide sufficient statistical power for gender stratification. Furthermore, our population-based case-control study was conducted in California's rural Central Valley, an area with substantial agricultural pesticide use. The high prevalence of pesticide exposure in this population provided sufficient statistical power to examine interactions between paraquat exposure and TBI on PD risk. However, study results may not be generalizable to populations with low pesticide exposure.
While both TBI and paraquat exposures weakly or moderately increased PD risk, the magnitude of the combined effect estimate was stronger than the sum of the TBI and PD effects alone, indicating a positive interaction on an additive scale. Our data suggest that multiple environmental factors may act together to increase the risk of PD beyond the effect of each risk factor alone, and that some individuals might be developing PD due to an accumulation of multiple exposures.
Supplementary Material
Abstract in Arabic
ACKNOWLEDGMENT
The authors thank the participants of this study and the neurologist community of the Central Valley of California for their continued support, S. Rhodes for feedback and editing of the manuscript, and M. Cockburn for lending GIS expertise and help in generating the paraquat exposure estimates.
Glossary
AORadjusted odds ratio
CIconfidence interval
GISgeographic information system
ORodds ratio
PDParkinson disease
RERIrelative excess risk due to interaction
RRrelative risk
TBItraumatic brain injury

AUTHOR CONTRIBUTIONS
Dr. Lee: analysis and interpretation of the data and writing of the manuscript. Dr. Bordelon: acquisition of data including physical examination of patients, contributed to manuscript writing. Dr. Bronstein: acquisition of data including physical examinations of patients, contributed to manuscript writing. Dr. Ritz: study design and acquisition of data, contributed to analysis and interpretation of the data, revisions of the manuscript, study supervision, and obtained funding.
DISCLOSURE
The authors report no disclosures relevant to the manuscript. Go to Neurology.org for full disclosures.
1. Manthripragada AD, Costello S, Cockburn MG, Bronstein JM, Ritz B. Paraoxonase 1, agricultural organophosphate exposure, and Parkinson disease. Epidemiology 2010;21:87–94. [PMC free article] [PubMed]
2. Ritz BR, Manthripragada AD, Costello S, et al. Dopamine transporter genetic variants and pesticides in Parkinson's disease. Environ Health Perspect 2009;117:964–969. [PMC free article] [PubMed]
3. Bower JH, Maraganore DM, Peterson BJ, McDonnell SK, Ahlskog JE, Rocca WA. Head trauma preceding PD: a case-control study. Neurology 2003;60:1610–1615. [PubMed]
4. Dick FD, De Palma G, Ahmadi A, et al. Environmental risk factors for Parkinson's disease and parkinsonism: the Geoparkinson study. Occup Environ Med 2007;64:666–672. [PMC free article] [PubMed]
5. Factor SA, Weiner WJ. Prior history of head trauma in Parkinson's disease. Mov Disord 1991;6:225–229. [PubMed]
6. Goldman SM, Tanner CM, Oakes D, Bhudhikanok GS, Gupta A, Langston JW. Head injury and Parkinson's disease risk in twins. Ann Neurol 2006;60:65–72. [PubMed]
7. Seidler A, Hellenbrand W, Robra BP, et al. Possible environmental, occupational, and other etiologic factors for Parkinson's disease: a case-control study in Germany. Neurology 1996;46:1275–1284. [PubMed]
8. Rugbjerg K, Ritz B, Korbo L, Martinussen N, Olsen JH. Risk of Parkinson's disease after hospital contact for head injury: population based case-control study. BMJ 2008;337:a2494. [PMC free article] [PubMed]
9. McCann SJ, LeCouteur DG, Green AC, et al. The epidemiology of Parkinson's disease in an Australian population. Neuroepidemiology 1998;17:310–317. [PubMed]
10. Taylor CA, Saint-Hilaire MH, Cupples LA, et al. Environmental, medical, and family history risk factors for Parkinson's disease: a New England-based case control study. Am J Med Genet 1999;88:742–749. [PubMed]
11. Sulzer D. Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. Trends Neurosci 2007;30:244–250. [PubMed]
12. Hutson CB, Lazo CR, Mortazavi F, Giza CC, Hovda D, Chesselet MF. Traumatic brain injury in adult rats causes progressive nigrostriatal dopaminergic cell loss and enhanced vulnerability to the pesticide paraquat. J Neurotrauma 2011;28:1783–1801. [PMC free article] [PubMed]
13. Costello S, Cockburn M, Bronstein J, Zhang X, Ritz B. Parkinson's disease and residential exposure to maneb and paraquat from agricultural applications in the central valley of California. Am J Epidemiol 2009;169:919–926. [PMC free article] [PubMed]
14. Kang GA, Bronstein JM, Masterman DL, Redelings M, Crum JA, Ritz B. Clinical characteristics in early Parkinson's disease in a central California population-based study. Mov Disord 2005;20:1133–1142. [PMC free article] [PubMed]
15. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 1992;42:1142–1146. [PubMed]
16. Langston JW, Widner H, Goetz CG, et al. Core assessment program for intracerebral transplantations (CAPIT). Mov Disord 1992;7:2–13. [PubMed]
17. Ritz B, Rhodes SL, Bordelon Y, Bronstein J. alpha-Synuclein genetic variants predict faster motor symptom progression in idiopathic Parkinson disease. PLoS One 2012;7:e36199. [PMC free article] [PubMed]
18. Ritz B, Costello S. Geographic model and biomarker-derived measures of pesticide exposure and Parkinson's disease. Ann N Y Acad Sci 2006;1076:378–387. [PMC free article] [PubMed]
19. Rull RP, Ritz B. Historical pesticide exposure in California using pesticide use reports and land-use surveys: an assessment of misclassification error and bias. Environ Health Perspect 2003;111:1582–1589. [PMC free article] [PubMed]
20. Goldberg DW, Wilson JP, Knoblock CA, Ritz B, Cockburn MG. An effective and efficient approach for manually improving geocoded data. Int J Health Geogr 2008;7:60. [PMC free article] [PubMed]
21. Rothman KJ. Epidemiology: An Introduction. New York: Oxford University Press; 2002.
22. Hosmer DW, Lemeshow S. Confidence interval estimation of interaction. Epidemiology 1992;3:452–456. [PubMed]
23. Wang A, Costello S, Cockburn M, Zhang X, Bronstein J, Ritz B. Parkinson's disease risk from ambient exposure to pesticides. Eur J Epidemiol 2011;26:547–555. [PMC free article] [PubMed]
24. Liou HH, Tsai MC, Chen CJ, et al. Environmental risk factors and Parkinson's disease: a case-control study in Taiwan. Neurology 1997;48:1583–1588. [PubMed]
25. Tanner CM, Kamel F, Ross GW, et al. Rotenone, paraquat, and Parkinson's disease. Environ Health Perspect 2011;119:866–872. [PMC free article] [PubMed]
26. Newell KL, Boyer P, Gomez-Tortosa E, et al. Alpha-synuclein immunoreactivity is present in axonal swellings in neuroaxonal dystrophy and acute traumatic brain injury. J Neuropathol Exp Neurol 1999;58:1263–1268. [PubMed]
27. Smith DH, Chen XH, Nonaka M, et al. Accumulation of amyloid beta and tau and the formation of neurofilament inclusions following diffuse brain injury in the pig. J Neuropathol Exp Neurol 1999;58:982–992. [PubMed]
28. Smith DH, Uryu K, Saatman KE, Trojanowski JQ, McIntosh TK. Protein accumulation in traumatic brain injury. Neuromolecular Med 2003;4:59–72. [PubMed]
29. Gentleman SM, Leclercq PD, Moyes L, et al. Long-term intracerebral inflammatory response after traumatic brain injury. Forensic Sci Int 2004;146:97–104. [PubMed]
30. Lenzlinger PM, Morganti-Kossmann MC, Laurer HL, McIntosh TK. The duality of the inflammatory response to traumatic brain injury. Mol Neurobiol 2001;24:169–181. [PubMed]
31. Schmidt OI, Heyde CE, Ertel W, Stahel PF. Closed head injury–an inflammatory disease? Brain Res Brain Res Rev 2005;48:388–399. [PubMed]
32. Frantseva M, Perez Velazquez JL, Tonkikh A, Adamchik Y, Carlen PL. Neurotrauma/neurodegeneration and mitochondrial dysfunction. Prog Brain Res 2002;137:171–176. [PubMed]
33. Graham DI, McIntosh TK, Maxwell WL, Nicoll JA. Recent advances in neurotrauma. J Neuropathol Exp Neurol 2000;59:641–651. [PubMed]
34. Stoll G, Jander S, Schroeter M. Detrimental and beneficial effects of injury-induced inflammation and cytokine expression in the nervous system. Adv Exp Med Biol 2002;513:87–113. [PubMed]
35. Unterberg AW, Stover J, Kress B, Kiening KL. Edema and brain trauma. Neuroscience 2004;129:1021–1029. [PubMed]
36. Goldman SM, Kamel F, Ross GW, et al. Head injury, alpha-synuclein Rep1, and Parkinson's disease. Ann Neurol 2012;71:40–48. [PMC free article] [PubMed]
37. Kay DM, Factor SA, Samii A, et al. Genetic association between alpha-synuclein and idiopathic Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet 2008;147B:1222–1230. [PubMed]
38. Maraganore DM, de Andrade M, Elbaz A, et al. Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA 2006;296:661–670. [PubMed]
39. Dinis-Oliveira RJ, Remiao F, Carmo H, et al. Paraquat exposure as an etiological factor of Parkinson's disease. Neurotoxicology 2006;27:1110–1122. [PubMed]
40. Kuter K, Nowak P, Golembiowska K, Ossowska K. Increased reactive oxygen species production in the brain after repeated low-dose pesticide paraquat exposure in rats. A comparison with peripheral tissues. Neurochem Res 2010;35:1121–1130. [PubMed]
Articles from Neurology are provided here courtesy of
American Academy of Neurology